Innovent Reports the Results of Mazdutide (IBI362) in P-III Trial for the Treatment of Adults with Overweight or Obesity
Shots:
- The P-III (GLORY-1) clinical trial evaluated the safety & efficacy of Mazdutide (4 or 6mg) vs PBO in Chinese patients (n=610) with overweight or obesity for a duration of 48wks.
- The study met its 1EPs with superor effects of Mazdutide vs PBO in terms of percentage change in body weight from baseline to wk32 & proportion of participants with a weight loss of ≥5% at wk32. The 2EPs were also met incl. the proportion of participants with a weight loss of ≥10% or ≥15%, changes in waist circumference, systolic BP, TG, LDL-C, total cholesterol, serum uric acid & ALT
- Based on these results, Innovent expects to submit an NDA to the NMPA in near term for its GLP-1R & GCGR dual agonist, Mazdutide
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports First Patient Dosing in the P-III (GLORY-2) Trial of Mazdutide (IBI362) in Chinese Adults with Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
